Menu Search
Equities

Royal Prima Tbk PT

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PRIM:JKT

Royal Prima Tbk PT

Actions
Health CareHealth Care Providers
  • Price (IDR)79.00
  • Today's Change1.00 / 1.28%
  • Shares traded4.68m
  • 1 Year change+36.21%
  • Beta0.2709
Data delayed at least 10 minutes, as of Feb 13 2026 09:03 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Royal Prima Tbk is an Indonesia-based healthcare services company. The Company provides hospital services, clinics, polyclinics, and related business activities. Its segments are RSU Royal Prima, RS Royal Prima Jambi, and Rumah Sakit Marelan. The general health services include Emergency, Outpatient, Inpatient, Radiology, Medical Rehab, Pharmacy, and Micturating Cysto-Urethrogram (MCU). The specialized health services include General Surgery, Internist, Voluntary Counseling and Testing (VCT), Intensive Care Unit (ICU), Cardiology, Urology, Pediatric care, Endoscopy, and others. Other services include Acupuncture, Anesthesia, Beauty & Wellness, Dermatology, Dental and Mouth, Endocrine, Digestive, Vascular, Neurology, Ear Nose Throat (ENT), Nutrient Consultancy, Oncology, Plastic Surgery, Pediatric Surgery, Neurosurgery, Ophthalmology, Psychology, Orthopedic, and others. The Company operates through Royal Prima Medan, Royal Prima Marelan, and Royal Prima Jambi hospitals.

  • Revenue in IDR (TTM)332.14bn
  • Net income in IDR-7.20bn
  • Incorporated--
  • Employees752.00
  • Location
    Royal Prima Tbk PTJl Ayahanda No 68AJAKARTA BARAT 11480IndonesiaIDN
  • Phone+62 2 188813182
  • Fax+62 2 180013181
  • Websitehttps://www.royalprima.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.